Information on temporary shortage of the medicinal product Xenical 120 mg hard capsules (orlistat)
20.07.2012
Roche d.o.o., the marketing authorisation holder for Xenical 120 mg hard capsules (orlistat), has informed the Agency for Medicinal Products and Medical Devices on temporary shortage of the aforementioned medicinal product. The shortage is due to the established difficulties in manufacturing and laboratory practice at manufacturing the intermediates and active substances at the Roche's manufacturing site at Roche Carolina Inc., Florence, South Carolina.
There is another product available on the Croatian market with the same active substance from another manufacturer, not affected by the shortage.
New informations on the availability of the medicinal product Xenical, will be promptly made publicly available.
